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Abstract
Background: Human papillomavirus (HPV) DNA testing plays a main role in the management of cervical cancer,
however to improve the specificity in cervical screening, there is a need to develop and validate different approaches
that can identify women at risk for progressive disease.
Nowadays, mRNA expression of viral E6 and E7 HPV oncogenes stands up as a potential biomarker to improve cervical
screening. We aimed to validate a method for RNA extraction, detect HPV mRNA expression and, assess the
relationship between E6/E7 mRNA expression and pathology of patients’ lesions and progression.
Methods: This study included 50 specimens that had been previously genotyped as HPV16, 18, 31, 33 and/or
45. Cervical swabs were extracted with three different RNA extraction methods -Nuclisens manual extraction
kit (bioMérieux), High Pure Viral RNA Kit (Roche) and RNeasy Plus Mini kit (Qiagen)-, and mRNA was detected
with NucliSens EasyQ HPV version 1 test (bioMérieux) afterwards. Association of oncogene expression with
pathology and lesion progression was analyzed for each extraction method.
Results: E6/E7 mRNA positivity rate was higher in samples analyzed with bioMérieux (62%), followed by Roche (24%)
and Qiagen (6%). Women with lesions and lesion progression showed a higher prevalence of viral RNA expression than
women that had not lesions or with lesion persistence. While bioMérieux revealed a higher sensitivity (77.27%), Roche
presented a higher PPV (75%) and an increased specificity (89.28%).
Conclusions: Extraction methods based on magnetic beads provided better RNA yield than those based in columns.
Both Nuclisens manual extraction kit (bioMérieux) and High Pure Viral RNA Kit (Roche) seemed to be adequate for E6/
E7 mRNA detection. However, none of them revealed both high sensitivity and specificity values. Further studies are
needed to obtain and validate a standard gold method for RNA expression detection, to be included as part of the
routine cervical screening program.
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Background
High-risk Human papillomavirus (HR-HPV) infection
persistence is a necessary feature to develop cervical
cancer, which is the third most common cancer in
women worldwide, and the second most common can-
cer in developing regions [1–3]. Cancer incidence and
mortality have decreased significantly since the intro-
duction of cancer screening, which started with the
Papanicolau test in 1940’s.
HPV genome has two oncogenes, E6 and E7, whose
expression increased when these genes are deregulated
[4]. Oncogene deregulation affects the normal running
of the host cell increasing cell cycle entry and loss of
differentiation over the cervical epithelium [5, 6]. The
integration of HPV DNA into the host genome is an im-
portant event in cancer development and in malignant
transformation of cervical lesions [7]. In patients with
squamous cell carcinomas, the virus genome usually is
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integrated into host cell and when HPV circular genome
integrates into host cell genome, E2 gene ORF (Open
Reading Frame) is broken to linearize virus genome so E2
function is altered [8]. In fact, HPV E2 gene regulates HPV
late gene expression [9]. Namely, HPV viral oncoprotein
expression differs among infection state (active, latent, or
persistent) [9–11].
Nowadays, cervical cancer screening is based on cytology
and/or HPV DNA detection [12, 13]. HPV DNA detection
reveals a high prevalence of transient and asymptomatic
infections but does not give any information about the in-
fection state [9]. Therefore, new approaches (biomarkers)
are being studied to improve cervical screening, minimize
patient anxiety, over-referral to colposcopy and treatment,
as well as to decreased related costs.
One of the most promising cervical cancer biomarkers
is the mRNA expression of viral E6 and E7 oncogenes,
since its association with the severity of cervical lesions
is well described in the literature [14]. In 2007, bioMérieux
launched NucliSens EasyQ HPV version 1 test, a real-time
nucleic acid amplification and multiple detection assay,
that qualitatively detects the expression of the oncogenic
E6/E7 mRNA from the five most common high HR-HPV
genotypes: HPV16, 18, 31, 33 and 45 [15, 16].
The present study aimed to assess E6/E7 mRNA as a
possible biomarker for cervical cancer by analyzing the
relationship between HPV E6/E7 mRNA expression and
the pathology and evolution of different lesions. As some
authors have reported the importance of RNA input
(both quality and quantity) prior to any HPV RNA assay
[17–19], we aimed to compare three different RNA ex-
traction methods in order to evaluate the impact of
extraction in RNA expression detection.
Methods
Patients and clinical samples
From 2010 to 2014, all women (n = 912) attending Con-
sultation of Sexually Transmitted Diseases and Gynaeco-
logical consultation at Basurto University Hospital
(Basque Country, Spain) were remitted to Clinical Micro-
biology and Infection Control Department to analyze their
samples, when a possible HPV infection was suspected.
Samples were collected following endo/ectocervical
swabbing with a cytobrush and, stored in PreservCyt
(Hologic. Inc., Marlborough, MA) transport medium at
room temperature until HPV presence or absence was
studied.
Lesions were classified by pathologists following Bethesda
system: 1) Negative (no lesion was found) 2) Low-grade
squamous intraepithelial lesion (LSIL) - atypical squamous
cells of undetermined significance (ASCUS) included- and,
3) High-grade squamous intraepithelial lesion (HSIL).
Cytology was repeated 2 years after samples collection
and, results were categorized into three groups depending
on lesion progression: 1) Persistence: women whose
cytological results had not changed in the last 2 years, 2)
Progression: women whose cytological results showed a
worsened process, and 3) Regression: women who had
cleared signs of infection.
Written and informed consent was obtained from
participants.
The study adhered to the declaration of Helsinki and
was approved by Ethical Committee of Clinical Research
of Euskadi (Code: PI2014016).
All methods were carried out in accordance with the
approval guidelines.
Genotype detection
HPV genotyping was performed using Cobas® HPV Test
(Roche Molecular Diagnostics, Mannheim, Germany)
and Beta-globin was used as an internal control to ensure
specimen adequacy.
Cobas® HPV Test detects up to 14 HR-HPV genotypes,
identifying HPV16 and 18 specifically, while detecting
“other HR-HPV genotypes” (31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 66) concurrently.
Samples that had been positive for “other HR-HPV ge-
notypes” with Cobas® HPV Test were therefore, sub-
jected to Linear Array HPV Genotyping Test kit (Roche
Molecular Diagnostics, Mannheim, Germany), to eluci-
date which specific HR-HPV genotypes were present in
each specimen. Linear Array HPV Genotyping Test is a
line-blot assay that detects 37 HPV genotypes (6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56,
58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82,
83, 84, IS39, and CP6108).
All samples from women who were positive for
HPV16, 18, 31, 33 and/or 45 were included for further
RNA analysis (n = 50).
RNA extraction
RNA was extracted with three different kits according
to manufacturer’s instructions: 1) Nuclisens manual ex-
traction kit (bioMérieux, Marcy l’Etoile, France)-RNA
was extracted from 200 μl of samples by NucliSENS
Lysis Buffer and NucliSENS® miniMAG® and eluted in
60 μl of elution buffer-, 2) High Pure Viral RNA Kit
(Roche Molecular Diagnostics, Mannheim, Germany) -
RNA was extracted from 200 μl of sample and eluted in
50 μl of Elution Buffer- and, 3)
RNeasy® Plus Mini kit (Qiagen, Hilden, Germany)
-RNA was extracted from 400 μl of sample and eluted in
50 μl of RNase-Free Water-.
RNAse-Free water was used as negative control in
each RNA extraction. Eluted RNA was stored at -20 °C
until E6/E7 analysis (never exceeding 2 weeks) and at
-80 °C, afterwards.
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E6/E7 oncogene expression
Oncogene expression was analyzed in each sample three
times (one for each RNA extraction method). Those sam-
ples that had been genotyped as positive for several tar-
geted HPV genotypes (HPV16, 18, 31, 33 and/or 45) were
analyzed once for each genotype and extraction method.
E6/E7 mRNA was detected by NucliSens EasyQ HPV
test version 1 (bioMérieux, Marcy l’Etoile, France) fol-
lowing manufacturer’s instructions, including an internal
control, human U1 small nuclear ribonucleoprotein spe-
cific protein A (U1A), to assess mRNA expression qual-
ity. Samples with no RNA expression were re-extracted
and oncogene expression was analyzed once again.
Data analysis
Positive predictive value (PPV), Negative predictive value
(NPV), sensitivity and specificity were calculated for
each extraction method. The concordance between dif-
ferent extraction methods was studied by the relative ob-
served agreement (Pr(a)) and Cohen’s kappa coefficient
(κ). Statistical results were categorized according to Lan-
dis and Koch classification: values lower than 0 indicates
no agreement, from 0 to 0.20 slight agreement, from
0.21 to 0.40 fair agreement, from 0.41 to 0.60 moderate,
from 0.61 to 0.80 substantial, and from 0.81 to 1 as
nearly perfect agreement [20].
Association of oncogene expression with pathology




The age range of enrolled women (n = 50) varied from
19 to 63 years (mean age34.96 ± 10.63 years). Among
these women, 42% (21/50) were infected with only one
HPV genotype (single HPV infection) while 58% (29/50)
were infected with more than one HPV genotypes
(multiple HPV infection). However, only 4/29 multiple
infections revealed the presence of more than one
HPV targeted genotype (HPV16, 18, 31, 33 and/or
45). All four samples were multiple infections of 2
HPV genotypes.
The most detected genotype was HPV16 (64%, 32/50)
followed by HPV45 (14%, 7/50), HPV18 (12%, 6/50),
HPV31 (10%, 5/50) and HPV33 (6%, 3/50).
According to Bethesda system, 8% of samples were
classified as HSIL (4/50), 36% (18/50) as ASCUS or LSIL
and 56% (28/50) as negative.
Nuclisens manual extraction kit (bioMérieux)
E6/E7 mRNA positivity rate was 62% (31/50). Although
the most detected genotype after DNA analysis was
HPV16, the most expressed genotype was HPV33 followed
by HPV18, HPV16, HPV31 and HPV45 (Table 1).
The results obtained by mRNA analysis showed con-
cordance with HPV-types from the genotyping methods
for all samples but one. This sample was classified as
positive for HPV16 and 45 genotypes according to DNA
genotyping while oncogene expression revealed positivity
for HPVs 16, 45 and 31.
Among E6/E7 mRNA positive samples (31/50), 54.84%
(17/31) belonged to women who presented lesions
(41.94% to women with ASCUS or LSIL and 12.90% to
women with HSIL), while for mRNA negative specimens
(19/50), 73.68% (14/19) corresponded to women without
cervical lesions. All women with high-grade lesions were
classified as positive for oncogene expression (Fig. 1).
Analysis of lesion evolution revealed that 94.44% of
women that had suffered from lesion progression, were
positive for E6/E7 mRNA detection while the percentage
dropped to 43.75% for women with lesion persistence
(Fig. 2). No women showed infection regression.
High pure viral RNA Kit (Roche)
Oncogene expression was detected in 24% (12/50) of
women. The most expressed genotype was HPV33 followed
by HPV18, HPV45, HPV31 and HPV16 (Table 1). The
same genotypes that had been detected by HPV DNA
genotyping, were detected by mRNA expression in each
sample, but for one specimen (which had been genotyped
as HPV16 and 45, but mRNA expression revealed presence
of HPV16, 45, 31 and 33).
Nine out of 12 (75%) women who were positive for E6/
E7 mRNA expression had some type of lesion (50%
women with ASCUS or LSIL and 25% with HSIL) (Fig. 1).
Among samples that were negative for oncogene ex-
pression (38/50), 65.79% (25/38) belonged to women
without lesion, 31.58% (12/38) to women with ASCUS
or LSIL and, 2.63% (1/38) to women with high-grade le-
sion. Concerning lesion evolution, none of tested women
had infection clearance. Only 6.06% of women with le-
sion persistence were positive for oncogene expression
Table 1 E6/E7 mRNA expression of each genotype and













HPV 16 (32) 22/68.75 6/18.75 2/6.25
HPV 18 (6) 5/83.33 3/50.00 0/0.00
HPV 31 (5) 2/40.00 1/20.00 1/20.00
HPV 33 (3) 3/100.00 2/66.67 0/0.00
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while the percentage increased up to 58.82% for women
with lesion progression (Fig. 2).
RNeasy® Plus Mini kit (Qiagen)
Only 6% of all specimens (3/50) analyzed after Qiagen
extraction, showed mRNA expression. No significant
relationship (p > 0.05) was detected between oncogene
expression and type of lesion. Due to the low number
of E6/E7 mRNA positive samples, data obtained with
this method was excluded for comparison with other
methods.
Comparison between bioMérieux and Roche RNA extraction
methods
While the NPV was similar for both extraction methods
(65.79% Roche vs. 73.68% bioMérieux), the PPV was
higher for Roche than for bioMérieux (75% vs. 54.84%,
respectively). Roche extraction method also showed a
higher specificity (89.28% vs.50%), however, its sensitivity
was lower (40.90% vs. 77.27%) when comparing to the
bioMérieux extraction method.
Considering that viral oncogenes should be expressed
in women with lesions but not in women without
Fig. 1 Pathology according to E6/E7mRNA expression in two different extraction methods. E6/E7 mRNA rates: positivity rate for E6/E7 mRNA
expression (mRNA+) and negativity rate for E6/E7 mRNA expression (mRNA-). Pathology was classified into three groups: 1) Normal (no lesion), 2)
Atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesion (LSIL) and, 3) High-grade squamous
intraepithelial lesion (HSIL). bioMérieux extraction method was Nuclisens manual extraction kit; Roche extraction method was High Pure Viral
RNA Kit
Fig. 2 Lesion progression according to E6/E7 mRNA expression in two different extraction methods. E6/E7 mRNA rates: positivity rate for E6/E7
mRNA expression (mRNA+) and negativity rate for E6/E7 mRNA expression (mRNA-). Lesion evolution was categorized into two groups: 1) Persistence:
women whose cytological results had not changed in the last 2 years and, 2) Progression: women whose cytological results showed a worsened
process. bioMérieux extraction method was Nuclisens manual extraction kit; Roche extraction method was High Pure Viral RNA Kit
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lesions, bioMérieux extraction method showed substan-
tial and nearly perfect observed agreement whenever
women presented some type of lesion (0.72 in LSILs and
1 in HSILs) whereas Roche extraction method, showed
nearly perfect agreement (0.89) for women without le-
sion (Table 2).
Analyzing lesion development, Roche extraction methods
revealed a nearly perfect agreement for women that showed
persistence in their lesions (0.95) whereas bioMérieux ex-
traction method showed substantial concordance in women
with worsened lesions (0.74).
When comparing the 2 RNA extraction methods
against each other, a moderate relative observed agree-
ment was seen regarding E6/E7 mRNA detection rate
(0.58) and lesion development (0.57 for women that
showed persistance and 0.60 for women with worsened
lesions). Concerning pathology, a substantial agreement
was found in women without lesion or with high-grade
lesions (0.61 and 0.75, respectively) while the concord-
ance was just moderate when studying in women with
low-grade lesions (0.50).
Considering Cohen’s kappa coefficient, agreement be-
tween methods was fair regarding E6/E7 mRNA detec-
tion rate (0.26), and pathology (0.26 bioMérieux and
0.32 Roche). Concerning lesion progression, Roche ex-
traction method showed moderate agreement (0.41)
whereas bioMérieux agreement was fair (0.26) (Table 3).
Discussion
mRNA detection has been suggested as a promising cer-
vical cancer prognosis biomarker, as it might elucidate
the state of infection in patients [21]. It is highly important
to analyze all possible oncogenic types, in order to estab-
lish a successful cervical screening. We analyzed 50 pa-
tients with oncogenic HPV genotypes (HPV16, 18, 31, 33
and/or 45), and up to 62% revealed mRNA expression.
While HPV16 was the most common genotype de-
tected in these samples, mRNA analysis revealed that
Table 2 The relative observed agreement concerning pathology and lesion progression in two RNA extraction methods
Analysis of each extraction method separately
Method The relative observed
agreement Pr(a)
Pathology Nuclisens manual extraction
kit (bioMérieux)
No lesion 0.5
ASCUS + LSIL 0.72
HSIL 1
High Pure Viral RNA Kit (Roche) No lesion 0.89
ASCUS + LSIL 0.33
HSIL 0.75




High Pure Viral RNA Kit (Roche) Same lesion 0.95
Worsened lesion 0.40
Comparison between biomerieux and Roche extraction methods
E6/E7 mRNA detection rate 0.58
Pathology No lesion 0.61
ASCUS + LSIL 0.50
HSIL 0.75
Lesion progression Same lesion 0.57
Worsened lesion 0.60
Pathology was categorized into three groups: 1) Normal (no lesion), 2) Atypical squamous cells of undetermined significance (ASCUS) or low-grade squamous
intraepithelial lesion (LSIL) and, 3) High-grade squamous intraepithelial lesion (HSIL). Lesion progression was divided into two groups: 1) women whose cytological
results had not changed in the last two years and, 2) women whose cytological results showed a worsened process
Table 3 Cohen’s kappa coefficient concerning E6/E7 mRNA
detection rate, pathology and lesion progression in two RNA
extraction methods




Pathology Nuclisens manual extraction
kit (bioMérieux)
0.26
High Pure Viral RNA Kit (Roche) 0.32
Lesion progression Nuclisens manual extraction
kit (bioMérieux)
0.26
High Pure Viral RNA Kit (Roche) 0.41
Comparison between biomerieux and Roche extraction methods
E6/E7 mRNA detection rate 0.26
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other genotypes such as HPV33 and 18 were more fre-
quently expressed. Differences in expression detection
might have to do with the sensitivity and specificity of
the method used. It is highly likely that very low levels
of HPV transcripts might not be detected and still, those
“low levels” might be enough for HPV to perform its ac-
tion in the infected cells. Integration, an important event
in the progression of the disease, might not be solely re-
sponsible for the progression of the disease, as presence
of only episomal forms has been detected in patients with
advanced cervical squamous cell carcinomas [22, 23].
However, integrated forms with overexpression of E6 and
E7 leading to transformation of cells might be detected
more frequently than episomal forms.
Validating a protocol for mRNA detection is essential,
as false positive and/or false negatives might translate into
increasing patient anxiety, over-referral to colposcopy and
treatment, as well as to increasing related costs. Our aim
was to compare three different RNA extraction methods
(Nuclisens manual extraction kit from bioMérieux, High
Pure viral nucleic acid kit from Roche and RNeasy Plus
Mini kit from Qiagen) and assess the difference found
when analyzing E6 and E7 oncogene expression.
Among the extraction methods, E6/E7 mRNA positiv-
ity rate was higher in samples analyzed with bioMérieux
(62%, 31/50), followed by Roche (24%, 12/50) and Qia-
gen (6%, 3/50). These results are in agreement with
other studies that compares these extraction methods
for human immunodeficiency virus [24]. bioMérieux ex-
traction method is based on cell lysis and magnetized
silica dioxide particles while Roche and Qiagen extrac-
tion methods are based on column techniques. It is well
described in the literature that extraction methods based
on magnetic beads provide a higher RNA yield and purity,
and less inhibitors compared to spin columns [25, 26].
Due to the low rate obtained with Qiagen extraction, this
method was excluded for further analysis.
Both bioMérieux and Roche extraction methods
showed similar results when comparing RNA expression,
type of lesion and evolution. Women with lesions
showed a higher prevalence of viral RNA expression
(54.84% and 75%, for bioMérieux and Roche, respect-
ively) while women that had not lesions revealed a lower
prevalence of viral mRNA (26.32% bioMérieux and
34.21% Roche). Women that had suffered from lesion
progression were mostly positive for HPV mRNA (94.4%
bioMérieux and 58.82% Roche), while viral expression
positivity was found to be lower in women that had
remained with the same type of lesion (43.75% bioMér-
ieux and 6.06% Roche). These results agreed with other
authors that suggested E6/E7 mRNA expression as a
prognostic factor for high-grade lesions and confirmed
viral oncogene expression association with severity of
cervical lesions [27–29].
We evaluated the concordance between bioMérieux
and Roche with lesion type and evolution, applying two
different coefficients, the relative observed agreement
and Cohen’s kappa. The relative observed agreement
was found to be from fair to nearly perfect for both ex-
traction methods while Cohen’s kappa revealed a fair to
moderate concordance. Agreement differences might be
explained due to the low number of samples included in
the study.
As reported by Ovestad et al., a test for screening
population should have both high sensitivity and specifi-
city values [30]. In our study, none of extraction
methods showed high values for both parameters. While
Roche method showed a higher PPV and specificity, bio-
Mérieux revealed a higher sensitivity, NPV and mRNA
positive rate. Moreover, regarding cost effectiveness, the
cost of RNA extraction plus oncogenes detection was
almost double for bioMérieux than Roche (8.5 and 4.9,
respectively). Nowadays, there is not a gold standard
test for oncogenes expression detection [31] and fur-
ther studies are needed to elucidate and validate a
standard protocol.
Conclusions
We demonstrated the importance of validating a proto-
col for HPV E6 and E7 oncogene expression detection.
Extraction methods based on magnetic particles pro-
vided better RNA yield than those based in columns.
Both Nuclisens manual extraction kit (bioMérieux) and
High Pure Viral RNA Kit (Roche) seemed to be adequate
for E6/E7 mRNA detection. However, none of them re-
vealed both high sensitivity and specificity values. Sensi-
tivity was proven to be essential when detecting viral
mRNA expression, as certain genotypes as well as epi-
somal forms, might not produce a high number of tran-
scripts to transform cells. Further studies are needed to
obtain and validate a standard gold method for RNA ex-
pression detection, to be included as part of the routine
cervical screening method.
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